| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/30/2004 | WO2004083240A2 Regulation of gene expression |
| 09/30/2004 | WO2004082720A1 Drug for treating hemophilia and method of treating hemophilia using the same |
| 09/30/2004 | WO2004082703A1 Combined use of g-csf with angiogenetic factor |
| 09/30/2004 | WO2004082574A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d5 (drd5) |
| 09/30/2004 | WO2004082573A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4) |
| 09/30/2004 | WO2004082567A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| 09/30/2004 | WO2004073603A3 Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity |
| 09/30/2004 | WO2004065578A3 Microparticles comprising polynucleotide adsorbed on the surface of or entrapped within the microparticles |
| 09/30/2004 | WO2004064785A9 Cancer therapy sensitizer |
| 09/30/2004 | WO2004063332A9 Cancer related genes |
| 09/30/2004 | WO2004060408A8 p53 TREATMENT OF PAPILLOMAVIRUS AND CARCINOGEN-TRANSFORMED CELLS IN HYPERPLASTIC LESIONS |
| 09/30/2004 | WO2004060295A3 Methods of inducing and maintaining immune tolerance |
| 09/30/2004 | WO2004050126A3 Compositions for treating or preventing angiogenesis-dependent symptoms |
| 09/30/2004 | WO2004038405A3 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) |
| 09/30/2004 | WO2004037164A3 Crosslinked compounds and methods of making and using thereof |
| 09/30/2004 | WO2004029070A3 Methods for blocking adipocyte differentiation and triglyceride accumulation with dual-specificity tyrosine- (y) - phosphorylation regulated kinase 4 (dyrk4) inhibitors |
| 09/30/2004 | WO2003103586A3 Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| 09/30/2004 | WO2003082200A3 Potent oncolytic herpes simplex virus for cancer therapy |
| 09/30/2004 | WO2003080105A9 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof |
| 09/30/2004 | WO2003062447A3 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 09/30/2004 | WO2003049703A3 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 09/30/2004 | US20040194160 Expression vector comprising nucleotide sequences coding glucocorticoid-induced leucine-zipper family related protein (GILR) and tissue specific regulatory regions for transformation and generation of animal models to identify glucocorticoid hormones regulated genes associated with apoptosis control |
| 09/30/2004 | US20040194159 Cloning pigs using donor nuclei from differentiated cells |
| 09/30/2004 | US20040192630 nucleic acid constructs containing a HexB encoding element and a HexA encoding element; used in the treatment of Tay-Sachs and Sandoff disease; delivering a vector to a brain cell |
| 09/30/2004 | US20040192629 Selectively inhibit the mutant while retaining wild-type gene expression to treat diseases caused by dominant mutants such as amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease; administering to the cell an siRNA specific for the target allele |
| 09/30/2004 | US20040192628 gene expression inhibition of the kinase to prevent neovascularization, treat cancer |
| 09/30/2004 | US20040192627 Mitochondrial genome replenishment |
| 09/30/2004 | US20040192625 administering an isolated nucleic acid molecule of the beta 2AR gene; gene therapy; beta 2-adrenergic receptors ( beta 2AR) gene |
| 09/30/2004 | US20040192607 Transcriptional regulation of the human beta3-adrenergic receptor gene |
| 09/30/2004 | US20040192593 Protease resistant ti-growth hormone releasing hormone |
| 09/30/2004 | US20040192588 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 09/30/2004 | US20040191909 Glycerol viral suspension absent of divalent metal cations or alkali metal cations and capable for presevation and storage of adenovirus particles |
| 09/30/2004 | US20040191905 Modulation of HIV replication by RNA interference |
| 09/30/2004 | US20040191893 Implantable drug delivery system comprised of sealed thermoplastic polymer in association with permeable membrane; gene therapy; toxicity testing |
| 09/30/2004 | US20040191866 Attenuated microorganisms for the treatment of infection |
| 09/30/2004 | US20040191843 Cytotoxic mixture comprising polypeptides for treatment and prevention of cell proliferfative disorders |
| 09/30/2004 | US20040191820 Using high throughput assay for detection and identification of modulators of telomeric complex binding activity; diagnosis and treatment of cell proliferative and age related disorders; antiproliferative agent |
| 09/30/2004 | US20040191818 Compositions and methods for diagnosing and treating autoimmune diseases |
| 09/30/2004 | US20040191800 Comprises nucleotide sequences coding protein which controls thermogenesis in human skeletal muscle and heart for prevention and treatment of obesity, cachexia, cardiovascular and muscular disorders |
| 09/30/2004 | US20040191791 Comprises nucleotide sequences coding sodium voltage gated channels for identifying modulators for treatment of epilepsy; diagnosis of seizure disorders |
| 09/30/2004 | US20040191773 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 09/30/2004 | US20040191767 Comprises nucleotide sequences coding hepatitis core protein fusion for generating vaccine to prevent infcetion and treat liver dysfunction; gene therapy and cell-mediated immune response |
| 09/30/2004 | US20040191756 Transgenic rodent for diagnosing and identifying modulator for treatment and prevention inflammatory disorders |
| 09/30/2004 | US20040191247 Use of il-18 inhibitors for treating or preventing cns injuries |
| 09/30/2004 | US20040191230 Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin |
| 09/30/2004 | US20040191228 Methods of kidney transplantation utilizing developing nephric tissue |
| 09/30/2004 | US20040191223 Combinatorial methods for inducing cancer cell death |
| 09/30/2004 | US20040191222 Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby |
| 09/30/2004 | US20040191221 Delivering heterologous gene to a periosteal cell of a mammal; gene expression; bone disorders, osteoarthritis and osteoporosis; antiinflammatory agents |
| 09/30/2004 | US20040191173 Metastasis models using green fluorescent protein (GFP) as a marker |
| 09/30/2004 | CA2855229A1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/30/2004 | CA2524255A1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/30/2004 | CA2522786A1 Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| 09/30/2004 | CA2522380A1 Specific inhibition of allorejection |
| 09/30/2004 | CA2519863A1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/30/2004 | CA2519412A1 Combined use of g-csf and factors having angiogenic action |
| 09/29/2004 | EP1462521A1 Human p53 splice variant displaying differential transcriptional activity |
| 09/29/2004 | EP1462102A1 A method for promoting gonadal growth in an animal |
| 09/29/2004 | EP1461450A1 T-bet compositions and methods of use thereof |
| 09/29/2004 | EP1461449A2 System for monitoring bacterial tumor treatment |
| 09/29/2004 | EP1461441A1 Flavivirus vaccine delivery system |
| 09/29/2004 | EP1461436A1 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 09/29/2004 | EP1461427A2 Methods for targeted expression of therapeutic nucleic acid |
| 09/29/2004 | EP1461358A1 Ifnar2 muteins, their production and use |
| 09/29/2004 | EP1461087A1 Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| 09/29/2004 | EP1461073A2 Peptide agonists of prostate-specific antigen, and uses therefor |
| 09/29/2004 | EP1461071A1 Muscle transcription factors |
| 09/29/2004 | EP1461066A1 The use of il6r/il6 chimera in nerve cell regeneration |
| 09/29/2004 | EP1461052A2 Nucleic acid injected into hepatic vein lumen and delivered to primate liver |
| 09/29/2004 | EP1461014A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 09/29/2004 | EP1156812A4 Multiparticulate formulation |
| 09/29/2004 | EP0956045B1 Assembly-deficient herpesvirus vaccine |
| 09/29/2004 | EP0699079B1 Bioactive and/or targeted dendrimer conjugates comprising genetic materials |
| 09/29/2004 | CN1533433A Method for virus propagation |
| 09/29/2004 | CN1533284A Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases |
| 09/29/2004 | CN1533283A Use of osteopontin for treatment and/or prevention of neurologic diseases |
| 09/29/2004 | CN1533242A Foot and mouth disease virus vaccine |
| 09/29/2004 | CN1532281A RFecombination of carcino-emhyyonic antigen gene fragment and gene vaccine |
| 09/29/2004 | CN1531972A Method for treating tumor |
| 09/29/2004 | CN1168736C Composition and method for delivery of nucleic acids |
| 09/28/2004 | US6797703 Gene therapy using TGF-β |
| 09/28/2004 | US6797702 Methods and compositions comprising DNA damaging agents and P53 |
| 09/28/2004 | US6797696 Contacting a bodily fluid with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (haah) polypeptide to form a complex and detecting the complex; treating malignant neoplasms by inhibiting haah. |
| 09/28/2004 | US6797691 With pigment epithelium-derived factor (pedf) |
| 09/28/2004 | US6797511 Basis of its ability to bind to presenilin 1; for treatment of alzheimer's disease |
| 09/28/2004 | US6797502 Polypeptide for use in the treatment of hypertriglyceridemia, atherosclerosis and eating disorders |
| 09/28/2004 | US6797494 Containing locus control regions (lcr) from epstein-barr virus; globulins; genetic engineering |
| 09/28/2004 | US6797491 Human papilloma virus treatment |
| 09/28/2004 | US6797281 Esters of I-carnitine or alkanoyl I-carnitines |
| 09/28/2004 | US6797271 Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides |
| 09/28/2004 | US6797269 Mesenchymal stem cells as immunosuppressants |
| 09/28/2004 | US6797265 Therapy for metabolism disorders; gene therapy |
| 09/28/2004 | CA2298414C Method for preventing and treating hearing loss using a neurturin protein product |
| 09/24/2004 | WO2005111058A1 Intracellular delivery of osteoinductive proteins and peptides |
| 09/23/2004 | WO2004081199A2 Novel compositions and methods for the treatment of immune related disease |
| 09/23/2004 | WO2004081198A2 Methods for modulating angiogenesis with apelin compositions |
| 09/23/2004 | WO2004081189A2 Multimodality imaging of reporter gene expression using a novel fusion vector in living cells and organisms |
| 09/23/2004 | WO2004081188A2 Non-toxic membrane-translocating peptides |
| 09/23/2004 | WO2004081167A2 Expression vectors comprising the mcmv ie2 promoter |
| 09/23/2004 | WO2004081052A1 Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalopathies |